-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, due to the resonance of multiple factors such as favorable policies, influx of talents, capital increase, and increased investment in corporate research and development, China's biopharmaceutical industry has developed rapidly
.
At present, this field has become a national strategic emerging industry and one of the industries with high potential in the capital market
.
According to data, the domestic biopharmaceutical market will be about 387 billion yuan in 2020, and this figure is expected to grow to 1.
3 trillion yuan by 2030
.
With the rapid development of the biopharmaceutical industry, the demand for equipment from pharmaceutical companies will continue to grow (Source: Pharmaceutical Network) In short, the biopharmaceutical industry has a huge market space.
Biopharmaceutical industry base to accelerate the development of biopharmaceutical industry
.
In this context, the industry expects that while China's biopharmaceutical industry will continue to be promoted, it will also continue to move in the direction of high quality, and the results will continue to emerge
.
In fact, many pharmaceutical companies and provincial and municipal biopharmaceutical industry bases have gradually begun to produce results
.
It is worth mentioning that the analysis believes that under the rapid development of the domestic biopharmaceutical industry, in addition to starting, the biopharmaceutical equipment industry will also usher in good opportunities
.
It is understood that in the face of the vast blue ocean of the biopharmaceutical market, Chutian Technology, Tofflon and other pharmaceutical machine companies have already actively deployed
.
For example, Chutian Science and Technology established a subsidiary Microsphere Bio to overcome the important nodes of key biopharmaceutical technologies; Tofflon invested in the construction of a pharmaceutical system equipment production base construction project of nearly 500 million yuan to serve the development of the biopharmaceutical industry
.
According to the third quarter report of Chutian Technology in 2021, in the first three quarters, the company's biopharmaceutical equipment segment revenue and orders accounted for about 40%; It is also mentioned that the overall business of the company in the first three quarters of 2021 is progressing well, and the biopharmaceutical business has benefited from the rapid expansion of domestic and foreign vaccine companies, which shows the strong demand for biopharmaceutical equipment.
.
In the case of strong demand for biopharmaceutical equipment, analysts predict that China's pharmaceutical equipment market will increase from the current 100 billion yuan to about 200 billion yuan in 2025, and this 200 billion yuan scale growth will include a once-in-a-lifetime related to biopharmaceuticals.
Contributed income from sexual technology products, fillers, excipients,
etc.
However, it should be noted that the current domestic back-end equipment including filling lines and post-packaging lines can basically meet the needs of biopharmaceutical companies, but in high-end biopharmaceutical equipment, such as some front-end equipment with relatively high technical difficulty , the domestic market is still dominated by foreign pharmaceutical machine giants.
Therefore, the development of high-end equipment may be the goal of the next stage of domestic pharmaceutical equipment companies
.
In general, under the rapid development of the domestic biopharmaceutical industry, pharmaceutical machine companies need to seize the opportunity to accelerate the promotion of the pharmaceutical equipment industry into a new round of upgrading by introducing advanced technologies, and continue to meet the needs of pharmaceutical companies.
Demand for advanced, higher-end, more efficient, and more environmentally friendly biopharmaceutical equipment
.
.
At present, this field has become a national strategic emerging industry and one of the industries with high potential in the capital market
.
According to data, the domestic biopharmaceutical market will be about 387 billion yuan in 2020, and this figure is expected to grow to 1.
3 trillion yuan by 2030
.
With the rapid development of the biopharmaceutical industry, the demand for equipment from pharmaceutical companies will continue to grow (Source: Pharmaceutical Network) In short, the biopharmaceutical industry has a huge market space.
Biopharmaceutical industry base to accelerate the development of biopharmaceutical industry
.
In this context, the industry expects that while China's biopharmaceutical industry will continue to be promoted, it will also continue to move in the direction of high quality, and the results will continue to emerge
.
In fact, many pharmaceutical companies and provincial and municipal biopharmaceutical industry bases have gradually begun to produce results
.
It is worth mentioning that the analysis believes that under the rapid development of the domestic biopharmaceutical industry, in addition to starting, the biopharmaceutical equipment industry will also usher in good opportunities
.
It is understood that in the face of the vast blue ocean of the biopharmaceutical market, Chutian Technology, Tofflon and other pharmaceutical machine companies have already actively deployed
.
For example, Chutian Science and Technology established a subsidiary Microsphere Bio to overcome the important nodes of key biopharmaceutical technologies; Tofflon invested in the construction of a pharmaceutical system equipment production base construction project of nearly 500 million yuan to serve the development of the biopharmaceutical industry
.
According to the third quarter report of Chutian Technology in 2021, in the first three quarters, the company's biopharmaceutical equipment segment revenue and orders accounted for about 40%; It is also mentioned that the overall business of the company in the first three quarters of 2021 is progressing well, and the biopharmaceutical business has benefited from the rapid expansion of domestic and foreign vaccine companies, which shows the strong demand for biopharmaceutical equipment.
.
In the case of strong demand for biopharmaceutical equipment, analysts predict that China's pharmaceutical equipment market will increase from the current 100 billion yuan to about 200 billion yuan in 2025, and this 200 billion yuan scale growth will include a once-in-a-lifetime related to biopharmaceuticals.
Contributed income from sexual technology products, fillers, excipients,
etc.
However, it should be noted that the current domestic back-end equipment including filling lines and post-packaging lines can basically meet the needs of biopharmaceutical companies, but in high-end biopharmaceutical equipment, such as some front-end equipment with relatively high technical difficulty , the domestic market is still dominated by foreign pharmaceutical machine giants.
Therefore, the development of high-end equipment may be the goal of the next stage of domestic pharmaceutical equipment companies
.
In general, under the rapid development of the domestic biopharmaceutical industry, pharmaceutical machine companies need to seize the opportunity to accelerate the promotion of the pharmaceutical equipment industry into a new round of upgrading by introducing advanced technologies, and continue to meet the needs of pharmaceutical companies.
Demand for advanced, higher-end, more efficient, and more environmentally friendly biopharmaceutical equipment
.
